StrideBio, Inc., a Durham, NC-based company developing novel AAV vectors for in vivo gene therapies, closed a Series A Financing Round of $15.7m.
The round was led by Hatteras Venture Partners with participation from Takeda Ventures, UCB Ventures, and Alexandria Venture Investments. In conjunction with the funding, Jayson Punwani, PhD, Partner, Takeda Ventures, and Erica Whittaker, PhD, Vice President, Head of UCB Ventures joined StrideBio’s Board of Directors.
The company will use the funds to move multiple programs towards the clinic.
StrideBio provides an AAV (Adeno-associated virus) vector development platform that uses structure-guided evolution to discover novel capsids with a reduced antibody binding profile in multiple tissues, including: liver, muscle, eye and central nervous system, with improved properties for in vivo gene delivery applications.
The underlying technology is based on the work of co-founders, Dr. Aravind Asokan at the University of North Carolina at Chapel Hill and Dr. Mavis Agbandje-McKenna at the University of Florida.